BioInvent discusses recent Pfizer immunotherapy alliance

February 28, 2017 Christoph Graener

Three years after setting out to turn BioInvent around, company president and CEO Michael Oredsson tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how the company is developing its immunotherapy offering. With tumor-associated myeloid cells, BioInvent secured a deal with Pfizer at the end of 2016, while it intends to go it alone with its regulatory T cell approach.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Oredsson – President and CEO, BioInvent

Previous Article
Increase the value of your asset: Think with the end in mind
Increase the value of your asset: Think with the end in mind

Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The T...

Next Article
Market-ready Advicenne seeks partners and EUR 40 million VC funds

With a focus on pediatric neurology and nephrology, Dr. Luc-André Granier, founder, CEO and medical directo...